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LETTER TO THE ED/TOR 
U S E O F P R A Z I Q U A N T E L I N P O P U L A T I O N S A T R I S K O F 
N E U R O C Y S T I C E R C O S I S 
After our original communication5, two 
further instances of seizures fol lowing 
praziquantel administrat ion during the 
treatment of intestinal teniasis, became known 
to the authors ( O R I H U E L A A . , and P L A T A 
O., personal communications). Dr. Orihuela's 
case, a 39 year-old male with an intestinal 
infection by T . saginata, had previously 
received a well tolerated, but unsuccessful, 400 
mg/day course of albendazole during 3 days, 
on account of which, he was later given 50 
mg/kg/day of P Z Q . On the second day of 
therapy, he experienced several episodes of 
secondarily generalized right partial seizures. 
The other patient corresponded to a 45 year-old 
female that received a single 20 mg/kg dose of 
PZQ because of an intestinal hymenolepiasis. 
Several hours later, she experienced an episode 
of partial seizure, secondarily generalized. 
Brain C A T scans in both patients revealed 
characteristic hypodense cystic lesions of an 
until then asymptomatic, parenchymal 
neurocysticercosis, which responded to 
conventional 15 m g / k g / d a y courses of 
albendazole during two weeks1. 
Praziquantel is an acylated isoquinole-
pyrazine derivative with broad antiparasitic 
spectrum, used worldwide in both the treatment 
and control of schistosomiasis6, as well as in other 
trematodes and most cestode infections 4. 
Contrary to oxamniquine, another antiparasitic 
currently utilized in mass chemotherapy 
programs for the control of schistosomiasis, 
which is known to cause transient E E G and 
occasional seizures2, praziquantel is devoid of 
intrinsic neurological toxici ty 3 . The two 
additional cases of praziquantel-associated 
seizures, mentioned herein, clearly reinforce 
our initial suggestion that the compound must 
be administered with caution in those areas 
where cysticercosis is known to occur. 
Furthermore, the onset of seizures or other 
related neurological symptoms in an otherwise 
healthy individual receiving praziquantel, must 
prompt exhaustive clinical and laboratory 
evaluations, including the performance of a 
C A T scan, in order to rule out brain 
parenchymal cysticercosis. 
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